Date: 2013-12-04
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: AstraZeneca (UK) Amgen (USA - CA)
Product: MEDI9929 (AMG 157)
Action
mechanism: monoclonal antibody. MEDI9929 (AMG 157) is a monoclonal antibody that binds to and inhibits thymic stromal lymphopoietin (TSLP) from interacting with its receptor. TSLP is a cytokine that is believed to play a critical role in the start of the allergic cascade, specifically the inflammatory response, and is generated by lung tissue when an allergen is introduced. Studies have also shown higher amounts of TSLP were produced in the lung tissue of individuals with asthma compared to healthy individuals, and the TSLP gene has been associated with both childhood and adult allergic asthma.
Disease: severe asthma
Therapeutic area: Allergic diseases – Inflammatory diseases – Respiratory diseases
Country: Bulgaria, Czech Republic, Hungary, Israel, Japan, Latvia, Lithuania, Serbia, Slovakia, South Africa, Ukraine, USA
Trial
details: The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma (NCT02054130).
Latest
news: * On December 4, 2013, AstraZeneca and Medimmune have provided informations on a phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of MEDI9929 in adult subjects with inadequately controlled, severe asthma.
